Watch 2006 synthesis bulletin: Recommendations for clinical practice: Use of PET-FDG in the cancers of the kidney, the prostate, the testicle and the bladder;Recommandations pour la pratique clinique: Utilisation de la TEP-FDG dans les cancers du rein, de la prostate, du testicule et de la vessie

Bulletin du Cancer

Volumn 93, Issue 12, 2006, Pages 1228-1232

  Bourguet, Patrick ^a   Planchamp, François ^b   Montravers, Françoise ^c   Vincendeau, Sébastien ^d   Courbon, Frédéric ^e   Edeline, Véronique ^f   Helal, Badia Ourkia ^g   Rossi, Dominique ^h   Villers, Arnauld ⁱ  

^a CENTRE EUGÈNE MARQUIS   (France)

^b FNCLCC   (France)

^c HÔPITAL TENON   (France)

^d PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f INSTITUT CURIE   (France)

^g HÔPITAL ANTOINE BÉCLÈRE   (France)

^h HÔPITAL NORD   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CLINICAL PRACTICE; HEALTH CARE UTILIZATION; HEALTH CENTER; HEALTH PRACTITIONER; HOSPITALIZATION; HUMAN; MEDICAL ASSESSMENT; MEDICAL EDUCATION; MEDICAL EXPERT; MEDICAL RESEARCH; MEDICAL SOCIETY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REVIEW; TESTIS CANCER;

EID: 33846078433     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Kang DE, White RL, Jr., Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004; 171: 1806-9.
2. Jadvar H, Kherbache HM, Pinski JK, Conti PS. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol 2003; 60: 395-400.
3. Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003; 21: 3995-4000.
4. Kumar R, Chauhan A, Lakhani P, Xiu Y, Zhuang H, Alavi A. 2-Deoxy-2-[F-18] fluoro-D-glucose-positron emission tomography in characterization of solid renal masses. Mol Imaging Biol 2005; 7: 431-9.
5. Chang CH, Shiau YC, Shen YY, Kao A, Lin CC, Lee CC. Differentiating solitary pulmonary metastases in patients with renal cell carcinomas by 18F-fluoro-2-deoxyglucose positron emission tomography-a preliminary report. Urol Int 2003; 71: 306-9.
6. Schoder H, Herrmann K, Gonen M, Hricak H, Eberhard S, Scardino P, et al. 2- [18F] fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005; 11: 4761-9.
7. Chang CH, Wu HC, Tsai JJ, Shen YY, Changlai SP, Kao A. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int 2003; 70: 311-5.
8. Oyama N, Akino H, Suzuki Y, Kanamaru H, Miwa Y, Tsuka H, et al. Prognostic value of 2-deoxy-2- [F-18] fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 2002; 4: 99-104.
9. Morris MJ, Akhurst T, Larson SM, Ditullio M, Chu E, Siedlecki K, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005; 11: 3210-6.
10. Lassen U, Daugaard G, Eigtved A, Hojgaard L, Damgaard K, Rorth M. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 2003; 30: 396-402.
11. Becherer A, De Santis M, Karanikas G, Szabo M, Bokemeyer C, Dohmen BM, et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 2005; 54: 284-8.
12. Pfannenberg AC, Oechsle K, Bokemeyer C, Kollmannsberger C, Dohmen BM, Bares R, et al. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors-prospects for management. World J Urol 2004; 22: 132-9.
13. Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 2005; 32: 1412-7.